Relmada Therapeutics (RLMD) Misses Q4 EPS by 1c

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($0.84), $0.01 worse than the analyst estimate of ($0.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance
• TD Cowen on Oracle (ORCL): 'Solid 4Q & Guide'